bluebird bio Inc (BLUE) Receives Average Recommendation of “Hold” from Brokerages

Shares of bluebird bio Inc (NASDAQ:BLUE) have been assigned an average rating of “Hold” from the twenty-six analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $193.76.

A number of research firms have commented on BLUE. Canaccord Genuity reissued a “buy” rating and issued a $250.00 price target on shares of bluebird bio in a research note on Thursday, February 1st. Maxim Group reissued a “hold” rating and issued a $200.00 price target on shares of bluebird bio in a research note on Thursday, February 22nd. Morgan Stanley reissued an “equal weight” rating and issued a $152.00 price target (up previously from $151.00) on shares of bluebird bio in a research note on Monday, February 26th. William Blair reissued a “buy” rating on shares of bluebird bio in a research note on Friday, March 16th. Finally, CIBC began coverage on shares of bluebird bio in a research note on Thursday, December 21st. They issued a “market perform” rating for the company.

How to Become a New Pot Stock Millionaire

NASDAQ:BLUE traded down $1.40 during mid-day trading on Friday, hitting $170.75. 930,454 shares of the stock traded hands, compared to its average volume of 932,098. The stock has a market cap of $8,534.77, a P/E ratio of -22.15 and a beta of 2.06. bluebird bio has a 12-month low of $74.45 and a 12-month high of $236.17.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The company had revenue of $4.17 million during the quarter, compared to analysts’ expectations of $7.11 million. During the same period in the prior year, the firm earned ($1.88) EPS. bluebird bio’s quarterly revenue was up 169.0% on a year-over-year basis. equities analysts anticipate that bluebird bio will post -8.39 earnings per share for the current year.

In related news, COO Susanna Gatti High sold 17,262 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total transaction of $3,381,798.42. Following the completion of the sale, the chief operating officer now directly owns 28,512 shares in the company, valued at approximately $5,585,785.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jason Cole sold 1,129 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $173.38, for a total transaction of $195,746.02. Following the sale, the insider now owns 19,945 shares of the company’s stock, valued at $3,458,064.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 70,598 shares of company stock valued at $13,656,589. Company insiders own 3.90% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its position in bluebird bio by 6.4% during the 4th quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock valued at $682,366,000 after purchasing an additional 231,697 shares during the period. Franklin Resources Inc. increased its position in bluebird bio by 41.3% during the 4th quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock valued at $122,337,000 after purchasing an additional 200,900 shares during the period. Orbimed Advisors LLC increased its position in bluebird bio by 20.5% during the 3rd quarter. Orbimed Advisors LLC now owns 481,946 shares of the biotechnology company’s stock valued at $66,195,000 after purchasing an additional 82,146 shares during the period. Two Sigma Advisers LP increased its position in bluebird bio by 3,004.0% during the 4th quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock valued at $82,371,000 after purchasing an additional 447,600 shares during the period. Finally, Geode Capital Management LLC increased its position in bluebird bio by 9.0% during the 4th quarter. Geode Capital Management LLC now owns 454,997 shares of the biotechnology company’s stock valued at $81,034,000 after purchasing an additional 37,588 shares during the period.

COPYRIGHT VIOLATION NOTICE: “bluebird bio Inc (BLUE) Receives Average Recommendation of “Hold” from Brokerages” was published by WKRB News and is owned by of WKRB News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.wkrb13.com/2018/04/01/bluebird-bio-inc-blue-receives-average-recommendation-of-hold-from-brokerages.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply